Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Rallybio Corp (RLYB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates"
06/29/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Head of Investor Relations and Corporate Communications"
05/15/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/12/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/10/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/09/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Rallybio Reports First Quarter 2023 Financial Results -- RLYB212 Phase 1b Proof-of-Concept Study Results to be Presented at 31st Congress of the International Society of Thrombosis and Haemostasis in June 2023 -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated in 1Q 2023; Data Expected in 4Q 2023 -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $150.4 million cash, cash equivalents and marketable securities as of March 31, 2023; Provides Runway into 1Q 2025 --"
03/06/2023 10-K Annual Report for the period ended December 31, 2022
03/06/2023 8-K Quarterly results
Docs: "Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results -- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects – -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q 2025-- NEW HAVEN, Conn. March 6, 2023-- Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the fourth qu...",
"Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia -- RLYB212 Showed Rapid Elimination of Transfused, HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Clinical Findings and Safety Profile Consistent with Previously Reported Data; Continue to Support the Potential for RLYB212 as a Prophylactic Treatment for FNAIT -- -- Company Expects to Present Results at a Scientific Conference in 2023 --"
02/09/2023 SC 13G/A FMR LLC reports a 8.6% stake in RALLYBIO CORP
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/01/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/31/2023 8-K Quarterly results
01/23/2023 SC 13G/A Tekla Capital Management LLC reports a 4.6% stake in Rallybio Corp.
12/01/2022 8-K Quarterly results
11/17/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
11/14/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and among the Company and J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters named in Schedule A thereto",
"Form of Pre-Funded Warrant",
"Opinion of Ropes & Gray LLP"
11/14/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/10/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/07/2022 8-K Quarterly results
Docs: "Rallybio Reports Third Quarter 2022 Financial Results -- Preliminary results from Phase 1b study of RLYB212 showed rapid and complete elimination of transfused platelets in all subjects to date; Proof-of-concept data expected in 1Q 2023 -- -- Positive 100 mg results of Phase 1study of RLYB116 showed reduction of >99% in free C5 with the potential for weekly or less frequent dosing -- NEW HAVEN, Conn. November 7, 2022-- Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent program and corporate developments. “We made tremendous progre..."
09/28/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia -- Preliminary data from the ongoing Phase 1b study shows RLYB212 rapidly and completely eliminates transfused HPA-1a positive platelets -- -- Proof-of-Concept Data Expected in 1Q 2023--"
08/16/2022 EFFECT Form EFFECT - Notice of Effectiveness:
08/15/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/08/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/08/2022 8-K Quarterly results
Docs: "Rallybio Reports Second Quarter 2022 Financial Results -- Emerging data from Phase 1b study of RLYB212 shows rapid and complete elimination of transfused HPA-1a positive platelets -- -- Phase 1study of RLYB116 ongoing; initial single dose safety, PK, and PD data expected for the 30 mg dose in the 4Q 2022-- NEW HAVEN, Conn. August 8, 2022-- Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent program and corporate developments. “We continue to progress our pipeline toward planned upcoming milestones. We are pleased to see that the emergi..."
08/02/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors NEW HAVEN, Conn. August 2, 2022-- Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has appointed Wendy K. Chung, M.D., Ph.D., to its Board of Directors. “Wendy is a tremendous addition to our Board of Directors. Her extensive clinical experience and deep scientific expertise will be a valued asset as we continue to advance our current product portfolio as well as bring additional candidates into our pipeline. We look forward to learning from her expertise and insights,” said Martin Mackay, Ph.D., Chairman and Chief Executive Officer at R..."
06/07/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
06/06/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/02/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy